The DOI matches its Crossref record.
Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
Open accessAbstract
Serum CA 19-9 antigen concentrations were measured in 246 patients with benign and histologically confirmed malignant gastrointestinal diseases. The CA 19-9 concentration was above the upper limit of the normal range (0-37 U/ml) in 76% of patients with pancreatic carcinoma, 73% of patients with cholangiocarcinoma, 42% of patients with gastric carcinoma, and 22% of patients with hepatoma. High CA 19-9 concentrations were found mainly in patients with a metastasised cancer, whereas 71% of patients with a localised carcinoma had normal CA 19-9 concentrations. All of the patients with benign gastric diseases had normal CA 19-9 values. Moderately increased concentrations were found in 15-36% of the patients with benign pancreatic, liver, and biliary tract diseases. alpha-fetoprotein was a better marker for hepatomas than CA 19-9. CA 19-9 was better than carcinoembryonic antigen in differentiating malignant from benign diseases. The results indicate that the CA 19-9 assay is not completely specific for cancer but serves as a valuable adjunct, especially in the diagnosis of pancreatic carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Patel, A. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00744-3 · Cited by 425
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313030003 · Cited by 398
Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis
Ali, A. H., Tabibian, J. H., Nasser‐Ghodsi, N., Lennon, R. J., DeLeon, T., Borad, M. J., Hilscher, M., Silveira, M. G., Carey, E. J., & Lindor, K. D. (2018) · Hepatology · doi:10.1002/hep.29730 · Cited by 140
Metadata
- Authors
- Jalanko, H., Kuusela, P., Roberts, P., Sipponen, P., Haglund, C. A., & Mäkelä, O.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 1984-02
- Volume
- 37
- Issue
- 2
- Pages
- 218-222
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W2061879846
- Cited by
- 162
- References
- 0
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. https://app.cochat.ai/papers/10.1136/jcp.37.2.218
- The paper
- Jalanko, H., Kuusela, P., Roberts, P., Sipponen, P., Haglund, C. A., & Mäkelä, O. (1984). Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. Journal of Clinical Pathology. https://doi.org/10.1136/jcp.37.2.218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
